This

"don't think people realize how big this is"

This is par for the course with Nemus at this stage.

VBIO can trade at 7x the market cap of Nemus, while they have no cash, no pipeline schedule and IP that seems to lack behind Nemus. The monkeys follow the monkeys in the cannabis/cannabinoid sector and unfortunately theres no monkeys on the nemus train right now.

On a side note.

AXIM Biotech got analyst coverage today, with a price target representing a 1 billion dollar market cap.

Absolutely bananas. As ridiculous as that may be, should bode well for our valuation. Our time will be soon in being overvalued like them.

I would not be too concerned with the financing. The fact is that Nemus is by the book, and they now have a 20 million war chest.

If Schneider Brothers made a bad investment decision with a former client, it may have been that they were looking the other way, or they were unaware. The look-away approach is what every single bank does in the world, hence the loan crisis of 2008. Financing goes hand-in-hand with greed, and sometimes it works out, sometimes it doesnt. This one outlier is simply a blemish that essentially all financial firms have, whether its public or not.

All that matters is that this raise was designed to accelerate multiple targets into trials. We sit and wait, and valuations will propel with Phase 1/2a trials and additionals MSRA data.

It is absolutely phenomenal how under the radar this is...at some point you kinda hope the OTC cannabis circus clowns take notice so this could get to where it deserves

Remember when Regeneron just posted 1Q17 Eylea Sales of 860+ Million Dollars...

Remember when they partnered with OCUL in December to develop a new, better, formulation of Eylea with OCUL's technology.

I do!

With great news comes the robot bashers. It was inevitable.

20 Million cash infusion is instant validation.

THIS. "To our knowledge, this is one of the largest single investments in a cannabinoid-based biotech at our stage of development.

"Our investment firm views the cannabinoid therapeutic space as a transformative and disruptive opportunity in drug development. We were attracted to Nemus based on the vision and progress achieved by the management team, as well as the Company's strategic relationship with the University of Mississippi and the associated intellectual capital that collaboration provides. We believe that there is significant value in Nemus and we look forward to unlocking the true potential of the product pipeline."

I look forward to the fear-mongererss along with the crazy monkeys that get on board. Will be a fun boat to be on.

Lets go boys.

Our speculation can rest at peace. 20 Million is a huge cash grab to fund early trials and pave way for much higher valuations and partnerships/future funding.

Excited for the next 9 months. Amazing News.

Thanks to everybody on the board for their insight and heavy analysis. We're all better for it!

Vinpat a few questions since it looks like you've been in this since 2015..

1) The lack of promotion may be their way of being legit and not attracting pump teams, however, don't they owe it to their previous investors who've funneled millions of dollars in capital for the early stages of research?

Raising funds now at a 0.25 PPS means 40,000,000 shares added for a paltry $10 million, which as we know now with their therapies, doesnt go very far. Previous cash investments were supposed to get them through Phase 1 trials, allowing the PPS to rise, and raise another round at a decent price to keep dilution within reason. But they burned through every last dollar without a whisper of Phase 1 for any targets.

Can they raise at higher levels regardless of PPS?

2) For the most part, timeline has been way off as far as expectations from any analyst or any investor in particular. One has to believe that trials have to be close...what is your Date timeline expectation for NB1111 based on the most recent filing....

"Historically, Phase 2 studies in glaucoma are conducted over 28-days and patients place the test compound in one eye and the reference comparator in the other eye, thereby acting as their own controls. Given that IOP data is objectively measured, we will decide whether to conduct a subsequent Phase 2b study or go directly to a larger Phase 3 clinical trial based on the quality of the data collected in the Phase 2a study and the advice provided by FDA."

Stock goes down 5% on $500 of trading activity. Straight garbage manipulation. They wont let it breathe for a f*cking day.

Meanwhile VBIO blows through a 40 million market cap....

What are we missing guys

Some "ride" we've been on. 4 positive press releases and the company loses half its value.

OTC casino

Yep this is all that really matters. The partnerships they made for drug formulation means that everything is in play for clinical trials.

AXIM is an anomoly but also very indicative of the market sentiment on cannabinoid therapy. Which is EXTREMELY positive sentiment. They've just started Phase 2 Trials for IBS and they sit at a 600+ million market cap, even hitting high 700+s in April.


Funding for Clinical Trials + Phase 1 Trials = 100+ Million Market Cap.
Phase 2 Trials? Who knows. The market is very overzealous at times.

Side Note, miraculously, I have been wrong about everything in this security for 7 months. Pretty much dead wrong, so this'll prolly got to $3 USD

Kills me to leave, but I'm out. If not a bloodbath today, there will be in the following weeks.

Declines in grams sold and revenues are never good, especially with endless reports about the massive increases in overall number of medical cannabis users. This means their user base isnt growing, period.

They will crush REC sales but it will be a tumultuous 9 months ahead.

Explosive growth?

Acreage Valuations are only rising with $30,000/acre being the current market value.

With close to 2,000 Acres with Eagle's assets, thats $60,000,000 for the land alone, not including the black gold that lies beneath.

https://www.oilandgas360.com/everything-keeps-getting-bigger-texas-no-slowing-permian-basin-growth-spurt/

8 million revenue company Valued at 2.5 Million..... fuckin A.

Overvalued. They are light-years away from commercialization, and years away from core Phase 2 trials.

All biotechs are volatile, regardless of what stage of pre-clinical or trials. This is proper re-setting from the over-exuberance.

Isn't it amazing how they move in unison down.

If you think you have control in the markets, you are wrong! The crooks will live on, the only way to beat them is to look away and hold-on.

Earnings report should come this week or the next. I expect it to silence the fear-mongerers and show they have been able to hold customer loyalty.

Then upcoming cataylsts to look for, Organic Recertification, International Export license, further capital deployment into expansion to up that 26,000kg

The likelihood is that the the very early stages of retail shops will start to materialize through approvals, but it will be a slow process for each province.

This will be great for margins from the get-go.

E-Commerce will not only provide the backbone for the initial rush, but may actually be they key to long-term sustainability. Canopy's development of "Main Street" is very telling of the dedication to a full fledged e-commerce operation, so we should be looking as Shareholders for a similer unveiling of a dedication to Organigram's e-commerce position, and mobile platform.

Death of Retail stores is congruent across all industries. Once users have commited to brands, products, they will seek comfort in ordering product from their couch. The current medical system in place actually curtails to an Amazon-like development for pot and ancillary products.

There is no doubt that Denis and Greg Engel recognize this.

Does not have any bearing.

GW Pharma does all their work in the UK where Cannabis is banned. They work within legal bounds, as does Nemus.

Any "legal" talk that ever comes about is nonsense and fear mongering. Its not 1995 anymore, the sentiment has changed and regardless of a few bad apples, there is almost universal agreement in the medicinal benefits of breaking down the cannabis plant to use its component, or mirror its components with synthetics as most companies are doing. Not to mention, ALL of the companies besides GW are years from commercialization, so the positive sentiment will only get stronger.

NB1111 is still very much a lead candidate or dual-lead.

November 15 Press Release:

"NB1111 has performed above expectations in the ability to lower IOP in these animal models. We want to further explore the neuroprotective effects of cannabinoids upon the optic nerve and move the ophthalmology program into human testing. I am also happy to report that our colleagues at the University of Mississippi have been able to develop an early ocular formulation of our CBD analogue, and in doing so, expands our ocular program into a full-fledged ophthalmology platform that could address multiple eye diseases beyond glaucoma, including diseases of the retina," noted Brian Murphy, MD, MBA, Nemus CEO and Chief Medical Officer.

March 15th, 2017

03/20/17 -- NEMUS Bioscience, Inc. (OTCQB: NMUS) announced that the company has signed a development agreement with Nanomerics Ltd. of the United Kingdom, to develop a topical ocular formulation of tetrahydrocannabinol-valine-hemisuccinate (THCVHS), the prodrug of THC, which is the active component of Nemus drug candidate NB1111 being developed for the treatment of glaucoma. The aim of the agreement is to conduct initial studies assessing the preparation of clinical-grade eye drops using the patented Molecular Envelope Technology (MET) developed by Nanomerics. Work under the agreement will commence on a future date to be determined by Nemus in connection with its development plans and corporate objectives.

Been a month since last press release, biggest gap in 6 months. Reaaaaaaaly need some Fire to light this.

Amazing how undervalued this company is in relation to its peers. You would think that this should show a steady walk-up, considering the press releases from the December-March and the advancement towards trials. The round of funding in August 2015 was supposed to take NB1111 into trials, so we're almost pulling into 2 years now, bound to hear some developemnt.

InMed Pharma is trading at a 55million market cap with a pipeline that is incredible small, and well behind Nemus in timeline: https://www.inmedpharma.com/pipeline/

Can you believe this POS! What a fuckin train wreck.

2.2 million market cap when they did over 1.7 million in sales in 1st quarter?!?!?

Remarkable pull-back.

The sector is so grossly impacted by news media that investors are completely blind to the impending value of OGI and the rest of the superpower LP pack. Shocking sell off.

The legislation has all but guaranteed all of the big LP's to be set up to make 100-200mil in revenue from July 2018-July2019 on the very low end.

The fact that this isnt caked into the market cap is bananas.

INMed is running on air right now. $45 million market cap. All Pre-Clinical. Probably 8 months behind Nemus in even getting trials off the ground, not to mention they have only 2 drugs in their pipeline!

I believe Nemus is at 6 with 5 listed on their website and NB1222 for CINV.

We've gotten a ton of news recently but something has to give.

Kinda crazy...board goes dead when what we've been waiting for is only 5 days away!!

Been a rollercoaster 6 months for sure, but its blue skies ahead.

The fact that Denis has always stated that growth for the purpose of growth doesn't benefit shareholders will pay off immensely this year. Aurora & Canopy has been diluting their ASSES off , Canopy with last weeks dilution of 1/3 of their market cap!

Focusing on concentrates, edibles, and topicals with TGS is the golden ticket. Growing a surpus of flower may be nice, but unlocking the power of the trim, shake, & second hand buds for high quality edibles and oils is where the real money lies ahead.

Multiday runs ahead

Boomtime. China Market will slaughter the domestic sales since there is a holdback in some areas for CBD products. Incredible growth prospects ahead.

25% lower share price than from the first press release on 3/27 regarding revenues in 1Q exceeding all of last year, and on pace for 400% growth at a bare minimum.

incredible. the OTC is bogus.

Crazy how they are much further behind and have a 6x market cap of Nemus. And going for the same targets. They are atleast a year away from Phase 1 trials and yet they are building enough hype to warrant that market cap.....

So what does Nemus warrant when they commence Phase 1 in the next few months.

Crazy.

New article out!

https://www.insiderfinancial.com/potnetwork-holdings-inc-otcmkts-potn-continues-to-run-up-the-charts/120611/

Tidal Bore
(R2)

23.6% THC / 0.07% CBD
Non-Organic

Beastly strain from organigram!

LOL!

You have to laugh. The best you can do as a retail investor is to research and go with your gut. Manipulation is relentless to shake out weak hands.

Blue skies ahead? Maybe.

Also, Cara's results are a great thing for Nemus, INMED, Zynerba.

Investiment sentiment from banks when companies liek GW Pharma or Cara are succesful with cannabinoid-based therapies will translate to them taking shots at other companies.

This is similar to the immuneoncology space in that the companies tackling it will be evaluated similar to their peers and any breakthroughs translate as positives across the industry.

Theres two distinctions.

Years from commercialization, sure.

Not years from rising market cap though. Funding is the only thing holding this back, as really there isnt a reason for big whales to come in unless they know Phase 1 & Phase 2 trials are fully funded.

AXIM is blitzing past a 800 million market cap somehow while in early stages of trials.

If Murphy can't secure funding with the data and studies in conjunction with U.M., than nobody can, and the data is insignificant as far as commercializing. If they secure funding and an investment bank believes in the science, the data will be more important than us early investors can even imagine.

Market Cap at 6 million, projected sales for 2017 8 million with already 1.7 mil written down in 1Q.

hmmm. can we say undervalued?

Feels like we're missing something with the bludgeoning thats happened..

Alas, the funding must come through. That is the game changer. The "larger capital raise" that they are working on getting through an investment bank has gotta be around the corner. 3 months since that press release. critical day ahead.

That small U.S. volume is indicitave of the lack of knowledge on this sector south of the border. Most people looking at the U.S. headlines today and tomorrow, this will be completely new information about Canada moving forward with legalization.

Shocking that its new information, but the reality of it. The clownshow trading U.S. cannabis penny stocks might wake up from their alternate reality today...

Can 930a tommorow come already?

All american outlets just getting the information out (even though its not really new information, we know how the finicky market acts like a 4-year old )

Expecting a lengthy line of buyers to come filing in!